Long-Term Follow-up of Patients with Uterine Fibroids after Treatment with the LHRH Agonist Buserelin

Matta, Wassim H. M.; Shaw, Robert W.; Nye, Malcolm

doi:10.1097/00006254-199001000-00028

Cited by 14 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, interest has grown in developing measures for cost containment, use of conservative and where possible non‐surgical techniques 2 . Attempts at medical treatment with progesterone, danazol and gestrinone and GnRH agonists have been disappointing 3–5 …”

Section: Introductionmentioning

confidence: 99%

Low‐dose mifepristone in treatment of uterine leiomyoma: A randomised double‐blind placebo‐controlled clinical trial

Bagaria¹,

Suneja²,

Vaid³

et al. 2009

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Low‐dose mifepristone in treatment of uterine leiomyoma: A randomised double‐blind placebo‐controlled clinical trial

Bagaria¹,

Suneja²,

Vaid³

et al. 2009

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

show abstract

“…This type of treatment is restricted to a 3-to 6-month interval, but when treatment stops, usually fibroids came back their pretreatment size. In addition, side effects include menopausal symptoms and bone loss with long term use (Matta et al, 1989;Lethaby et al, 2002;Wallach and Vlahos, 2004;Rackow and Arici, 2006;Sankaran and Manyonda, 2008). Levenorgestrel intrauterine systems (LNG-IUS) can also reduce bleeding association with leiomyomas (Starczewski and Iwanicki, 2000;Wildemeersch and Schacht, 2002;Soysal and Soysal, 2005;Sayed et al, 2010).…”

Section: Classification (Histological Types)mentioning

confidence: 99%

HEALTHY AND PATHOLOGICAL CHANGES OF MYOMETRIUM: PREGNANT MYOMETRIUM, UTERINE FIBROIDS AND LEIOMYOSARCOMA. Cambios normales y patológicos del miometrio: miometrio del embarazo, fibrosis uterina y leiomiosarcoma

Ciarmela

Islam

Lamanna

et al. 2016

Rev Arg de Anat Clin

View full text Add to dashboard Cite

El miometrio, la pared muscular del útero, puede modificar su misma masa y las propiedades celulares en el embarazo y también en los tumores como el leiomioma y el leiomiosarcoma. El leiomioma, dicho también fibroma, es un tumor benigno del útero y se considera como una de las causas más frecuentes de infertilità en el período reproductivo femenino. El leiomiosarcoma, en cambio, es un tumor maligno y agresivo de la musculatura lisa uterina. La presente revisión discute las características generales del leiomioma y el leiomiosarcoma y los relativos tratamientos clínicos actualmente usados y además describe las características del miometrio normal en el embarazo. The myometrium, the muscular wall of the uterus, can modify its mass and cellular properties in pregnancy as well as in tumor conditions such as leiomyoma and leiomyosarcoma. Leiomyomas, also known as fibroids, are benign tumors of the uterus, considered to be one of the most frequent causes of infertility in reproductive years of women. Leiomyosarcomas in turn, are rare aggressive malignant uterine smooth-muscle tumors. The present review is discussing the general features of leiomyoma and leiomyosarcoma with their current treatments and also discussing the characteristics of normal pregnant myometrium and compare with leiomyoma.

show abstract

“…GnRH agonists are used to reduce the size of uterine leiomyomata prior to surgery by inducing a temporary artificial menopause 21–23 . The histological changes observed with the use of GnRH agonists have been variable, some studies reporting an increase in cellularity in the GnRHa‐treated leiomyomata, 24–26 others having found no difference between treated and untreated leiomyomata 27–29 and one study demonstrating a decreased cellularity 30 .…”

Section: The Effects Of Gnrh Agonists On Uterine Leiomyomatamentioning

confidence: 99%

Recent advances in the pathology of smooth muscle tumours of the uterus

Wilkinson

Rollason

2001

Histopathology

View full text Add to dashboard Cite

Smooth muscle tumours of the uterus are common and the majority are benign leiomyomas. However, there are some tumours which exhibit unusual morphological features or growth patterns that cause difficulty in their distinction from malignant neoplasms and those with endometrial stromal differentiation. Such lesions are reviewed in this article with detailed descriptions of their morphology, differential diagnosis and correlation with biological behaviour.

show abstract

Long-Term Follow-up of Patients with Uterine Fibroids after Treatment with the LHRH Agonist Buserelin

Cited by 14 publications

References 0 publications

Low‐dose mifepristone in treatment of uterine leiomyoma: A randomised double‐blind placebo‐controlled clinical trial

Low‐dose mifepristone in treatment of uterine leiomyoma: A randomised double‐blind placebo‐controlled clinical trial

HEALTHY AND PATHOLOGICAL CHANGES OF MYOMETRIUM: PREGNANT MYOMETRIUM, UTERINE FIBROIDS AND LEIOMYOSARCOMA. Cambios normales y patológicos del miometrio: miometrio del embarazo, fibrosis uterina y leiomiosarcoma

Recent advances in the pathology of smooth muscle tumours of the uterus

Contact Info

Product

Resources

About